In the News

May 12, 2020

Affera's Technology for Cardiac Arrhythmia Treatment Highlighted at the 2020 Heart Rhythm Society Late-Breaking Clinical Trial Session and Three Simultaneous Publications

December 19, 2019

Affera Announces World's First Successful Focal Pulsed Field Ablation in Patients

May 06, 2019

Affera's Technology For Cardiac Arrhythmia Treatment To Be Highlighted In 17 Scientific Sessions At The 2019 Heart Rhythm Society Meeting

May 07, 2018

Affera's Novel Technology For Cardiac Arrhythmia Treatment To Be Featured In 8 Scientific Sessions At The 2018 Heart Rhythm Society Meeting

March 04, 2016

Affera, Inc. relocates to 44 Pleasant Street in Watertown

Please reload

Publications & Media

May 08, 2020

A Lattice-Tip Focal Ablation Catheter that Toggles Between Radiofrequency and Pulsed Field Energy to Treat Atrial Fibrillation: A First-in-Human Trial

May 06, 2020

Pulsed-Field Ablation Using a Lattice Electrode for Focal Energy Delivery: Biophysical Characterization, Lesion Durability and Safety Evaluation

May 06, 2020

Focal Pulsed Field Ablation for Pulmonary Vein Isolation and Linear Atrial Lesions: A Preclinical Assessment of Safety and Durability

April 06, 2020

Feasibility, safety, and durability of porcine atrial ablation using a lattice‐tip temperature‐controlled radiofrequency ablation catheter

February 26, 2020

A Lattice-Tip Temperature-Controlled Radiofrequency Ablation Catheter for Wide Thermal Lesions

January 24, 2020

A Lattice-Tip Temperature-Controlled Radiofrequency Ablation Catheter: Durability of Pulmonary Vein Isolation and Linear Lesion Block

1 / 2

Please reload

"Point-by-Point Pulsed Field Ablation (+/- Radiofrequency Ablation) to Treat Atrial Fibrillation: A First-in-Human Trial" by Dr. Vivek Reddy
Each year, a few of the most impactful clinical trials are selected for the Heart Rhythm Society's Late-Breaking Clinical Trials sessions. Click to view Affera's system featured in the 2020 Late-Breaking Clinical Trials Session, Innovation Boulevard. 


We are a highly selective team of talented individuals, whose aim is to have a major impact on developing a breakthrough, life-saving technology.
We believe in maximizing the unique talents of each individual, empowering everyone to contribute on multiple levels. If you are innovative, resourceful and hands-on, we want you on our team!
View our current openings below, or e-mail for more information.


Doron Harlev

CEO, Founder

Doron is the founder and CEO of Affera, Inc.  Prior to Affera, Doron co-founded and served as co-CEO at Rhythmia Medical, which developed a unique Electroanatomical Mapping System for the treatment of Cardiac Arrhythmia. Acquired by Boston Scientific in 2012, Rhythmia became Boston Scientific’s cardiac mapping and navigation division, where Doron served as Vice President of Product and Technology. Prior to Rhythmia, Doron held a variety of roles in an elite R&D unit in the Israeli Ministry of Defense.


Doron is a prolific inventor holding over 140 issued and pending patents.  He is currently an advisor to a number of start-up companies, and serves as a Board member at Lexington Medical, Inc.  Doron holds an MBA from MIT Sloan, M.Sc. EE from Tel Aviv University and B.Sc. EE from the Technion Israel Institute of Technology.

Leon Amariglio

Board Member

Leon currently serves as the CEO of Lexington Medical, Inc. Previously, Leon co-founded Rhythmia with Doron and served as Vice President at Boston Scientific upon Rhythmia’s acquisition.


Prior to Rhythmia, Leon led business development at Ceragon Networks Ltd, a wireless equipment provider, and worked at Deutsche Bank Alex. Brown leading financing and mergers and acquisition transactions. Leon holds an MBA degree from Harvard Business School and a Masters of Engineering degree from the University of Cambridge.

Phil Fleck

Board Member

Phil has been designing and building medical devices for most of his professional career. He has brought numerous products to market and uses that expertise at Norwich Ventures to assess new technologies and assist entrepreneurs with building their companies. Previously, he served on the board of Rhythmia Medical.


Prior to joining Norwich Ventures, Phil was the President and COO of Arrow International, with oversight of worldwide R&D and manufacturing. In addition, Phil oversaw opening the first-ever manufacturing plant in the Czech Republic by a U.S. company. Phil serves on the executive board of the Life Sciences Greenhouse of Central Pennsylvania. Phil graduated with a B.S. from Lehigh University and attended Harvard’s Advanced Management Program.

Please reload

  • Twitter
  • LinkedIn Social Icon